Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Cardiovascular (CV) risk factors, particularly arterial hypertension, induce structural and functional changes in the heart and vasculature, termed CV remodeling.
• Cardiac remodeling involves alterations in left ventricular (LV) geometry, including LV hypertrophy (LVH), a significant CV risk marker.
• Vascular remodeling encompasses arterial wall changes like increased intima-media thickness, arterial stiffening, and impaired endothelial function.

Purpose of the Study:

• To investigate the role of Angiotensin-Converting Enzyme (ACE) inhibitors in managing cardiovascular remodeling.
• To assess the efficacy of ACE inhibitors in reversing cardiac and vascular remodeling, independent of blood pressure reduction.

Main Methods:

• Review of evidence on the effects of ACE inhibitors on CV remodeling.
• Analysis of studies examining changes in LV mass, LVH, arterial wall structure, and endothelial function.

Main Results:

• ACE inhibitors demonstrate effectiveness in controlling and reversing CV remodeling.
• These drugs reduce LV mass, regress LVH, and attenuate vascular atherosclerosis.
• ACE inhibitors improve vascular compliance and endothelial function, with sulfhydryl-containing agents enhancing nitric oxide release.

Conclusions:

• ACE inhibitors are crucial in counteracting CV remodeling driven by hypertension and other risk factors.
• Their benefits extend beyond blood pressure reduction, offering significant improvements in cardiac and vascular structure and function.
• Specific ACE inhibitors may provide additional vascular benefits through enhanced nitric oxide pathways.